Regional differences in self-reported screening, prevalence and management of cardiovascular risk factors in Switzerland

BMC Public Health

Fred Paccaud¹  Pedro Marques-Vidal¹ 

[1] Institute of Social and Preventive Medicine (IUMSP), Route de la Corniche 2, 1066 Epalinges, Switzerland

关键词: Switzerland;    Obesity;    Smoking;    Hypertension;    Dyslipidemia;    Diabetes;    Geographical differences;   

Others  :  1163729
DOI  :  10.1186/1471-2458-12-246

 received in 2011-12-20, accepted in 2012-03-28,  发布年份 2012

【 摘 要 】

Background

In Switzerland, health policies are decided at the local level, but little is known regarding their impact on the screening and management of cardiovascular risk factors (CVRFs). We thus aimed at assessing geographical levels of CVRFs in Switzerland.

Methods

Swiss Health Survey for 2007 (N = 17,879). Seven administrative regions were defined: West (Leman), West-Central (Mittelland), Zurich, South (Ticino), North-West, East and Central Switzerland. Obesity, smoking, hypertension, dyslipidemia and diabetes prevalence, treatment and screening within the last 12 months were assessed by interview.

Results

After multivariate adjustment for age, gender, educational level, marital status and Swiss citizenship, no significant differences were found between regions regarding prevalence of obesity or current smoking. Similarly, no differences were found regarding hypertension screening and prevalence. Two thirds of subjects who had been told they had high blood pressure were treated, the lowest treatment rates being found in East Switzerland: odds-ratio and [95% confidence interval] 0.65 [0.50-0.85]. Screening for hypercholesterolemia was more frequently reported in French (Leman) and Italian (Ticino) speaking regions. Four out of ten participants who had been told they had high cholesterol levels were treated and the lowest treatment rates were found in German-speaking regions. Screening for diabetes was higher in Ticino (1.24 [1.09 - 1.42]). Six out of ten participants who had been told they had diabetes were treated, the lowest treatment rates were found for German-speaking regions.

Conclusions

In Switzerland, cardiovascular risk factor screening and management differ between regions and these differences cannot be accounted for by differences in populations' characteristics. Management of most cardiovascular risk factors could be improved.

【 授权许可】

   
2012 Marques-Vidal and Paccaud; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Levi F, Lucchini F, Negri E, La Vecchia C: Trends in mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world. Heart 2002, 88:119-124.
• [2]Pickle LW, Gillum RF: Geographic variation in cardiovascular disease mortality in US blacks and whites. J Natl Med Assoc 1999, 91:545-556.
• [3]Jarvie JL, Johnson CE, Wang Y, Aslam F, Athanasopoulos LV, Pollin I, et al.: Geographic variance of cardiovascular risk factors among community women: the national Sister to Sister campaign. J Womens Health (Larchmt) 2011, 20:11-19.
• [4]Lawlor DA, Bedford C, Taylor M, Ebrahim S: Geographical variation in cardiovascular disease, risk factors, and their control in older women: British Women's Heart and Health Study. J Epidemiol Community Health 2003, 57:134-140.
• [5]Lei S, Yong-Yong X, Xiao-Han D, Chang-Sheng C: Geographical differences in blood pressure of male youth aged 17-21 years in China. Blood Press 2004, 13:169-175.
• [6]Chow CM, Donovan L, Manuel D, Johansen H, Tu JV: Regional variation in self-reported heart disease prevalence in Canada. Can J Cardiol 2005, 21:1265-1271.
• [7]Soljak M, Samarasundera E, Indulkar T, Walford H, Majeed A: Variations in cardiovascular disease under-diagnosis in England: national cross-sectional spatial analysis. BMC Cardiovasc Disord 2011, 11:12. BioMed Central Full Text
• [8]Marques-Vidal P, Arveiler D, Evans A, Amouyel P, Ferrières J, Luc G, et al.: Awareness, treatment and control of hyperlipidaemia in middle-aged men in France and Northern Ireland in 1991-1993: the PRIME study. Prospective epidemiological study of myocardial infarction. Acta Cardiol 2002, 57:117-123.
• [9]Pardell H, Roure E, Drygas W, Morava E, Nussel E, Puska P, et al.: East-west differences in reported preventive practices. A comparative study of six European areas of the WHO-CINDI programme. Eur J Public Health 2001, 11:393-396.
• [10]Marrugat J, Senti M: Why mortality from heart disease is low in France. High cholesterol may not have same effect on cardiovascular risk in southern Europe as elsewhere. BMJ 2000, 320:250.
• [11]Reich O, Weins C, Schusterschitz C, Thoni M: Exploring the disparities of regional health care expenditures in Switzerland: some empirical evidence. Eur J Health Econ 2011, in press.
• [12]Etat de la prévention du tabagisme dans les cantons [Status of smoking prevention among cantons] Office Fédéral de la Santé Publique [Federal Office of Public Health] 2011.
• [13]Cheng CL, Chen YC, Liu TM, Yang YH: Using spatial analysis to demonstrate the heterogeneity of the cardiovascular drug-prescribing pattern in Taiwan. BMC Publ Health 2011, 11:380. BioMed Central Full Text
• [14]Gerber PA, Spirk D, Brandle M, Thoenes M, Lehmann R, Keller U: Regional differences of glycaemic control in patients with type 2 diabetes mellitus in Switzerland: a national cross-sectional survey. Swiss Med Wkly 2011, 141:w13218.
• [15]Schweizerische Gesundheitsbefragung: Gesundheit und Gesundheitsverhalten in der Schweiz 1997 [Swiss Health Survey: Health behavior and health in Switzerland 1997]. Neuchâtel, Swtzerland: Bundesamt für Statistik [Federal Office of Statistics]; 2000.
• [16]IHA-GfK: Schweizerische Gesundheitsbefragung SGB 2002--Schlussbericht zur Datenerhebung [Swiss Health Survey 2002--Final Report on Data Collection]. Neuchâtel, Switzerland: Bundesamt für Statistik [Federal Office of Statistics]; 2003.
• [17]Faeh D, Bopp M: Excess weight in the canton of Zurich, 1992-2009: harbinger of a trend reversal in Switzerland? Swiss Med Wkly 2010, 140:w13090.
• [18]Danon-Hersch N, Marques-Vidal P, Bovet P, Chiolero A, Paccaud F, Pécoud A, et al.: Prevalence, awareness, treatment and control of high blood pressure in a Swiss city general population: the CoLaus study. Eur J Cardiovasc Prev Rehabil 2009, 16:66-72.
• [19]Ward PR, Noyce PR, Leger StAS: Are GP practice prescribing rates for coronary heart disease drugs equitable? A cross sectional analysis in four primary care trusts in England. J Epidemiol Community Health 2004, 58:89-96.
• [20]Firmann M, Marques-Vidal P, Paccaud F, Mooser V, Rodondi N, Waeber G, et al.: Prevalence, treatment and control of dyslipidaemia in Switzerland: still a long way to go. Eur J Cardiovasc Prev Rehabil 2010, 17:682-687.
• [21]Nanchen D, Chiolero A, Marques-Vidal PM, Cornuz J, Waeber G, Vollenweider P, et al.: Prescription de statines en prevention primaire: quel score de risque cardiovasculaire faut-il utiliser en Suisse? [Statin prescription in primary prevention: which cardiovascular risk score should be used in Switzerland?]. Rev Med Suisse 2010, 6:488-493.
• [22]Reiner Z, Catapano AL, De BG, Graham I, Taskinen MR, Wiklund O, et al.: ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011, 32:1769-1818.
• [23]Marques-Vidal P, Rodondi N, Bochud M, Pécoud A, Hayoz D, Paccaud F, et al.: Predictive accuracy and usefulness of calibration of the ESC SCORE in Switzerland. Eur J Cardiovasc Prev Rehabil 2008, 15:402-408.
• [24]Ito MK, Nanchen D, Rodondi N, Paccaud F, Waeber G, Vollenweider P, et al.: Statins for cardiovascular prevention according to different strategies: a cost analysis. Am J Cardiovasc Drugs 2011, 11:33-44.
• [25]Kaiser A, Vollenweider P, Waeber G, Marques-Vidal P: Prevalence, awareness and treatment of type 2 diabetes mellitus in Switzerland: the CoLaus study. Diabet Med 2012, 29(2):190-7.
• [26]American Diabetes Association: Screening for type 2 diabetes. Diabetes Care 2004, 27(Suppl 1):S11-S14.
• [27]American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2008, 31(Suppl 1):S55-S60.
• [28]Dyson PA, Kelly T, Deakin T, Duncan A, Frost G, Harrison Z, et al.: Diabetes UK evidence-based nutrition guidelines for the prevention and management of diabetes. Diabet Med 2011, 28:1282-1288.
• [29]World Health Organization: WHO/NMH/MNC/03. In Screening for type 2 diabetes. Edited by Department of Noncommunicable Disease Management. Geneva, Switzerland: World Health Organization; 2003:1-54.
• [30]OECD, WHO: OECD Reviews of Health Systems: Switzerland 2011. Paris, France: OECD Publishing; 2011.
• [31]Marques-Vidal P, Rodondi N, Bochud M, Chiolero A, Pecoud A, Hayoz D, et al.: Predictive accuracy of original and recalibrated Framingham risk score in the Swiss population. Int J Cardiol 2009, 133:346-353.
• [32]Kotseva K, Wood D, De Backer G, de Bacquer D, Pyörälä K, Reiner Z, et al.: EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. Eur J Cardiovasc Prev Rehabil 2010, 17:530-540.
• [33]Faeh D, Marques-Vidal P, Chiolero A, Bopp M: Obesity in Switzerland: do estimates depend on how body mass index has been assessed? Swiss Med Wkly 2008, 138:204-210.
• [34]Tolonen H, Koponen P, Aromaa A, Conti S, Graff-Iversen S, Grøtvedt L, et al.: Recommendations for organizing a standardized European Health Examination Survey. 22/2008, 1-13. Helsinki, Finland: Kansanterveyslaitos (KTL) [National Public Health Institute]; 2008.
• [35]Tolonen H, Koponen P, Aromaa A, Conti S, Graff-Iversen S, Grøtvedt L, et al.: Recommendations for the Health Examination Surveys in Europe. 21/2008, 1-181. Helsinki, Finland: Kansanterveyslaitos (KTL) [National Public Health Institute]; 2008.
• [36]Tolonen H, Koponen P, Aromaa A, Conti S, Graff-Iversen S, Grøtvedt L, et al.: Review of Health Examination Surveys in Europe. 18/2008. Helsinki, Finland: Kansanterveyslaitos (KTL) [National Public Health Institute]; 2008.